Amgen Inc.
AMGN Healthcare Drug Manufacturers General
Amgen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.8 billion, up 9.95% from fiscal 2024. In the quarter to June 2026, revenue grew 9.53%, EPS grew 65.4%, free cash flow grew 82.6% and total debt rose 1.96%, each against the same quarter a year earlier. Member of the S&P 500, Nasdaq 100 and Dow Jones; dividend growth for ten consecutive years, revenue growth for five.
Follow AMGN
Amgen Inc. (AMGN) Revenue
Amgen Inc.'s revenue for fiscal 2025 was $36.8B, up 9.95% from $33.4B in fiscal 2024. Over the twelve months to 30 June 2026 it was $38.1B. Over the past ten years it has ranged from $21.7B (fiscal 2015) to $36.8B (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 6 consecutive fiscal years. Amgen Inc. ranks 12th of 18 Drug Manufacturers General companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $36.8B | 9.95% |
| FY2024 | $33.4B | 18.57% |
| FY2023 | $28.2B | 7.09% |
| FY2022 | $26.3B | 1.32% |
| FY2021 | $26.0B | 2.18% |
| FY2020 | $25.4B | 8.83% |
| FY2019 | $23.4B | (1.62%) |
| FY2018 | $23.7B | 3.93% |
| FY2017 | $22.8B | (0.62%) |
| FY2016 | $23.0B | 6.14% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $10.1B | 16.66% |
| Mar 2026 | $8.6B | (12.65%) |
| Dec 2025 | $9.9B | 3.23% |
| Sep 2025 | $9.6B | 4.12% |
| 42 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| MRK Merck & Co., Inc. compare | $66.6B |
| ABBV AbbVie Inc. compare | $64.4B |
| PFE Pfizer Inc. compare | $63.7B |
| AZN AstraZeneca PLC compare | $61.4B |
| NVS Novartis AG compare | $56.7B |
| NVO Novo Nordisk A/S compare | $51.5B |
| BMY Bristol Myers Squibb Company compare | $49.2B |
| AMGN Amgen Inc. | $38.1B |
| GILD Gilead Sciences, Inc. compare | $30.5B |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on AMGN
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement